Atomoxetine and rivastigmine and its effects on attention in patients with non-demented Parkinson's disease

Trial Profile

Atomoxetine and rivastigmine and its effects on attention in patients with non-demented Parkinson's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2013

At a glance

  • Drugs Rivastigmine (Primary) ; Atomoxetine
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2013 New trial record
    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top